SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 31, 2005



                                   INYX, INC.

            (Exact name of registrant as specified in its charter)



       Nevada                         333-83152               75-2870720
       ------                         ---------               ----------
(State or other jurisdiction        (Commission             (I.R.S. Employer
   of incorporation)                 File Number)         Identification No.)

               825 Third  Avenue,  40th Floor,  New York,  NY 10022
                 (Address of principal executive offices) (Zip Code)

      Registrant's telephone number, including area code: (212) 838-1111

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule  13e-4(c)  under the
    Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 1.01   Entry into a Material Definitive Agreement

      On December 15, 2004,  the  Registrant  (acting  through its  wholly-owned
subsidiary  Inyx USA,  Ltd.)  signed an Asset  Purchase  Agreement  with Aventis
Pharmaceuticals Puerto Rico, Inc. ("APR") to acquire the real estate, equipment,
and certain contract rights  comprising its Manati,  Puerto Rico  pharmaceutical
manufacturing facility.

      Pursuant to the Asset Purchase  Agreement with APR, the Registrant entered
into manufacturing and supply and transition  services and support agreements on
March 31, 2005 with APR's parent company, the sanofi-aventis Group, in order for
the Registrant to continue to supply products and services to the sanofi-aventis
Group from the Manati pharmaceutical  manufacturing facility.  Payments are made
under these agreements pursuant to APR's 2005 standard costs of production.  The
term  of each  agreement  is 3  years,  however,  each  agreement  provides  for
automatic successive one year renewals for up to a total of five years.

      Pursuant to the Asset Purchase Agreement with APR,  Aeropharm  Technology,
Inc.   ("Aeropharm")   consented  to  the   assignment  of  its  March  5,  2004
manufacturing   and  supply   agreement  with  APR  to  the   Registrant.   Such
manufacturing  and supply  agreement  relates to the  manufacture  and supply of
Azmacort  chlorofluorocarbon ("CFC") pharmaceutical products by APR to Aeropharm
and its affiliate Kos Life Sciences,  Inc. ("Kos"). The agreement provides for a
5 year term  commencing  March 2004.  Termination  of the  agreement is possible
after the second year of the agreement provided 12 months notice is given.

Item 2.01   Completion of Acquisition or Disposition of Assets

      On March 31, 2005, the acquisition of the assets from APR was closed,  and
Registrant  assumed possession and control of the operations at such facilities.
Such assets  consisted of  approximately  140,000  square feet of improved  real
property in five buildings located on 9.5 acres in Manati, Puerto Rico, together
with all installed and existing equipment and fixtures. A total of $2,334,327 of
inventory was included.

      The assets were  acquired  from APR, a  subsidiary  of the  sanofi-aventis
Group. There was no pre-existing  relationship  between  Registrant,  any of its
affiliates,  any director or officer of  registrant or any associate of any such
director or officer,  and the seller.  Following  the closing,  Registrant  will
engage in certain contract manufacturing activities for sanofi-aventis.

      The consideration  for the purchase was $19.7 million,  which was obtained
from the proceeds of a credit facility  provided by Westernbank  Business Credit
Division of  Westernbank  Puerto Rico  ("Westernbank")  that is  discussed  in a
separate Current Report on Form 8-K filed on April 6, 2005.

      On April 1, 2005, as part of the Asset  Purchase  Agreement  with APR, the
Registrant  received  from APR a  general  assignment  of all  right,  title and
interest in, to and under all of the acquired assets.


                                       2
<PAGE>

Item 9.01.  Financial Exhibits, Pro Forma Financial Information and Exhibits.

      (a)  Financial Statements of Business Acquired

      As permitted by Form 8-K the historical financial  information required by
Regulation  S-X will be filed by an  amendment  to this Report no later than May
10, 2005.

      (b)  Pro Forma Financial Information

      As permitted by Form 8-K, the pro forma financial  information required by
Regulation  S-X will be filed by an  amendment  to this Report no later than May
10, 2005.

      (c) Exhibits

            Exhibit No.

      *2.1  Asset  Purchase  Agreement  dated as of December  15,  2004,  by and
            between Inyx USA, Ltd. and Aventis Pharmaceuticals Puerto Rico, Inc.
            filed as  Exhibit  10.34.1  to  Current  Report  on Form  8-K  filed
            December 20, 2004 is hereby incorporated herein by reference.

      2.2   General Assignment dated as of April 1, 2005, by and between Aventis
            Pharmaceuticals Puerto Rico Inc. and Inyx USA, Ltd.

      *Confidentiality  has been requested  with respect to certain  portions of
this Agreement.

                                   SIGNATURES

      Pursuant to the  requirement of the  Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                   INYX, INC.

                                    By:   /s/ Jack Kachkar
                                       ---------------------------------
                                          Jack Kachkar, Chairman

Dated:   April 6, 2005


                                       3
<PAGE>

                                INDEX TO EXHIBITS

      *2.1  Asset  Purchase  Agreement  dated as of December  15,  2004,  by and
            between Inyx USA, Ltd. and Aventis Pharmaceuticals Puerto Rico, Inc.
            filed as  Exhibit  10.34.1  to  Current  Report  on Form  8-K  filed
            December 20, 2004 is hereby incorporated herein by reference.

      2.2   General Assignment dated as of April 1, 2005, by and between Aventis
            Pharmaceuticals Puerto Rico Inc. and Inyx USA, Ltd.

      *Confidentiality  has been requested  with respect to certain  portions of
this Agreement


                                       4
{"company-data": {"conformed-name": "INYX INC", "cik": "0001114241", "assigned-sic": "2834", "irs-number": "752870720", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-83152", "film-number": "05737712"}, "business-address": {"street1": "825 THIRD AVENUE", "street2": "40TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022", "phone": "212-838-1111"}, "mail-address": {"street1": "825 THIRD AVENUE", "street2": "40TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10022"}, "former-company": {"former-conformed-name": "DOBLIQUE INC", "date-changed": "20000510"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D. C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 31, 2005

                                   INYX, INC.

            (Exact name of registrant as specified in its charter)

       Nevada                         333-83152               75-2870720
       ------                         ---------               ----------
(State or other jurisdiction        (Commission             (I.R.S. Employer
   of incorporation)                 File Number)         Identification No.)

               825 Third  Avenue,  40th Floor,  New York,  NY 10022
                 (Address of principal executive offices) (Zip Code)

      Registrant's telephone number, including area code: (212) 838-1111

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
    CFR 240.14a-12)

[ ] Pre-commencement  communications  pursuant to Rule  14d-2(b)  under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant to Rule  13e-4(c)  under the
    Exchange Act (17 CFR 240.13e-4(c))
Item 1.01   Entry into a Material Definitive Agreement

      On December 15, 2004,  the  Registrant  (acting  through its  wholly-owned
subsidiary  Inyx USA,  Ltd.)  signed an Asset  Purchase  Agreement  with Aventis
Pharmaceuticals Puerto Rico, Inc. ("APR") to acquire the real estate, equipment,
and certain contract rights  comprising its Manati,  Puerto Rico  pharmaceutical
manufacturing facility.

      Pursuant to the Asset Purchase  Agreement with APR, the Registrant entered
into manufacturing and supply and transition  services and support agreements on
March 31, 2005 with APR's parent company, the sanofi-aventis Group, in order for
the Registrant to continue to supply products and services to the sanofi-aventis
Group from the Manati pharmaceutical  manufacturing facility.  Payments are made
under these agreements pursuant to APR's 2005 standard costs of production.  The
term  of each  agreement  is 3  years,  however,  each  agreement  provides  for
automatic successive one year renewals for up to a total of five years.

      Pursuant to the Asset Purchase Agreement with APR,  Aeropharm  Technology,
Inc.   ("Aeropharm")   consented  to  the   assignment  of  its  March  5,  2004
manufacturing   and  supply   agreement  with  APR  to  the   Registrant.   Such
manufacturing  and supply  agreement  relates to the  manufacture  and supply of
Azmacort  chlorofluorocarbon ("CFC") pharmaceutical products by APR to Aeropharm
and its affiliate Kos Life Sciences,  Inc. ("Kos"). The agreement provides for a
5 year term  commencing  March 2004.  Termination  of the  agreement is possible
after the second year of the agreement provided 12 months notice is given.

Item 2.01   Completion of Acquisition or Disposition of Assets

      On March 31, 2005, the acquisition of the assets from APR was closed,  and
Registrant  assumed possession and control of the operations at such facilities.
Such assets  consisted of  approximately  140,000  square feet of improved  real
property in five buildings located on 9.5 acres in Manati, Puerto Rico, together
with all installed and existing equipment and fixtures. A total of $2,334,327 of
inventory was included.

      The assets were  acquired  from APR, a  subsidiary  of the  sanofi-aventis
Group. There was no pre-existing  relationship  between  Registrant,  any of its
affiliates,  any director or officer of  registrant or any associate of any such
director or officer,  and the seller.  Following  the closing,  Registrant  will
engage in certain contract manufacturing activities for sanofi-aventis.

      The consideration  for the purchase was $19.7 million,  which was obtained
from the proceeds of a credit facility  provided by Westernbank  Business Credit
Division of  Westernbank  Puerto Rico  ("Westernbank")  that is  discussed  in a
separate Current Report on Form 8-K filed on April 6, 2005.

      On April 1, 2005, as part of the Asset  Purchase  Agreement  with APR, the
Registrant  received  from APR a  general  assignment  of all  right,  title and
interest in, to and under all of the acquired assets.

                                       2
Item 9.01.  Financial Exhibits, Pro Forma Financial Information and Exhibits.

      (a)  Financial Statements of Business Acquired

      As permitted by Form 8-K the historical financial  information required by
Regulation  S-X will be filed by an  amendment  to this Report no later than May
10, 2005.

      (b)  Pro Forma Financial Information

      As permitted by Form 8-K, the pro forma financial  information required by
Regulation  S-X will be filed by an  amendment  to this Report no later than May
10, 2005.

      (c) Exhibits

            Exhibit No.

      *2.1  Asset  Purchase  Agreement  dated as of December  15,  2004,  by and
            between Inyx USA, Ltd. and Aventis Pharmaceuticals Puerto Rico, Inc.
            filed as  Exhibit  10.34.1  to  Current  Report  on Form  8-K  filed
            December 20, 2004 is hereby incorporated herein by reference.

      2.2   General Assignment dated as of April 1, 2005, by and between Aventis
            Pharmaceuticals Puerto Rico Inc. and Inyx USA, Ltd.

      *Confidentiality  has been requested  with respect to certain  portions of
this Agreement.

                                   SIGNATURES

      Pursuant to the  requirement of the  Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                   INYX, INC.

                                    By:   /s/ Jack Kachkar
                                       ---------------------------------
                                          Jack Kachkar, Chairman

Dated:   April 6, 2005

                                       3
INDEX TO EXHIBITS

      *2.1  Asset  Purchase  Agreement  dated as of December  15,  2004,  by and
            between Inyx USA, Ltd. and Aventis Pharmaceuticals Puerto Rico, Inc.
            filed as  Exhibit  10.34.1  to  Current  Report  on Form  8-K  filed
            December 20, 2004 is hereby incorporated herein by reference.

      2.2   General Assignment dated as of April 1, 2005, by and between Aventis
            Pharmaceuticals Puerto Rico Inc. and Inyx USA, Ltd.

      *Confidentiality  has been requested  with respect to certain  portions of
this Agreement

                                       4